Ian Rodger

Evidence against the Involvement of Chronic Cerebrospinal Venous Abnormalities in Multiple Sclerosis. A Case-Control Study

Rodger IW, Dilar D, Dwyer J, Bienenstock J, Coret A, Coret-Simon J, Foster G, Franchetto A, Franic S, Goldsmith CH

Analgesic targets: today and tomorrow

Rodger IW

Inhibition of COX pathway in experimental myocardial infarction

Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A

Correction to: J. Zacher, D. Feldman, R. Gerli et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin 2003; 19(8): 725-736.

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

Zacher J, Feldman D, Gerli R, Scott D, Hou S-M, Uebelhart D, Rodger IW, Ozturk ZE, group FTEOS

Cyclooxygenase-2 (COX-2) in acute myocardial infarction: cellular expression and use of selective COX-2 inhibitor

Saito T, Rodger IW, Shennib H, Hu F, Tayara L, Giaid A

Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2

Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret J-P, Friesen RW, Gordon R, Greig G

Corrigendum to “Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret” [Neuropharmacology 38 (1999) 289–297]

Robichaud A, Tattersall FD, Choudhury I, Rodger IW

Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats (vol 78, pg 708, 2000)

Savoie C, Chan CC, Rodger IW, Robichaud A

Erratum: Selective potentiating effect of RS14203 on a serotoninergic pathway in anesthetized rats

Savoie C, Chan C-C, Rodger IW, Robichaud A